Abstract |
Treatment of human alpha-linolenic acid deficiency (ALAD) with ethyl linolenate is reported. The patient's scaly dermatitis nearly disappeared after 5-d supplementation with 0.1 mL ethyl linolenate. Pretreatment content of various n-3 fatty acids in RBC was 0-15% of healthy controls. After 14 d of supplementation, cholesterol and triglycerides were reduced by 70% of pretreatment values, 22:5n-3 and 22:6n-3 increased three- to fourfold while 18:3n-3 and 20:5n-3 remained low, indicating a rapid elongation and desaturation of 18:3n-3 in ALAD. Urinary excretion of PGI2-M was approximately 10 times higher than in healthy control subjects, while PGI3-M excretion was low. Linolenate supplementation increased PGI2-M excretion twofold, while PGI3-M remained near detection limit. Platelet capacity to synthesize TXA2, and urinary excretion of TXB2+3-M were nearly unaffected by supplementation. The results confirm that the minimal daily requirement of alpha-linolenic acid is 0.2-0.3% of total energy.
|
Authors | K S Bjerve, S Fischer, K Alme |
Journal | The American journal of clinical nutrition
(Am J Clin Nutr)
Vol. 46
Issue 4
Pg. 570-6
(Oct 1987)
ISSN: 0002-9165 [Print] United States |
PMID | 3310599
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Eicosanoic Acids
- Fatty Acids
- Linoleic Acids
- Linolenic Acids
- Thromboxanes
- Linoleic Acid
- Epoprostenol
- ethyl linolenate
|
Topics |
- Aged
- Aged, 80 and over
- Diet
- Eicosanoic Acids
(biosynthesis)
- Epoprostenol
(metabolism)
- Erythrocytes
(metabolism)
- Fatty Acids
(blood)
- Female
- Humans
- Linoleic Acid
- Linoleic Acids
(deficiency)
- Linolenic Acids
(administration & dosage)
- Nutrition Disorders
(diet therapy, metabolism)
- Thromboxanes
(metabolism)
|